Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency
22 Aug 2019
FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA
Mundipharma announces exclusive license and supply agreement with Prestige Biopharma for Tuznue® (HD201)
2 Jul 2019
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
Invokana® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis
11 Jun 2019
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
Mundipharma announces exclusive outsourcing distribution agreement with Egis Pharmaceuticals for Pelmeg▼® in Central and Eastern Europe